On March 31, 2026, Kitchener, Ontario-based health-tech startup myStoria closed a $1.625M seed round led by Graphite Ventures, with participation from Conexus Venture Capital, the Adrenaline Fund, Phoenix Fire Fund, and a group of strategic angels. The funding will be used to expand the company's AI-powered care coordination platform — a mobile-first iOS and Android product designed to solve one of reproductive health's most persistent problems: the burden placed on patients to become their own project managers, medical historians, and care coordinators when navigating complex conditions like endometriosis, PCOS, and infertility.

Why It Matters

The femtech funding environment in early 2026 has been robust ($314M in Q1 alone, per Femtech Insider's tracker), but most capital has flowed to hardware, telehealth prescribing platforms, and clinical-grade wearables. myStoria's seed round represents the care coordination/patient navigation category — a quieter but structurally important segment that addresses the systemic problems patients face even when good individual clinicians exist. If the platform achieves scale, it creates valuable longitudinal health data that could support research, inform clinical guidelines, and potentially become a defensible data asset for the company.

The platform's core mechanism is what myStoria calls a "Context Engine." Users upload health records, appointment notes, test results, photos, and symptom logs to a centralized AI-organized archive. The AI synthesizes this fragmented history into a structured format designed for both patient comprehension and clinical clarity — then surfaces personalized appointment prep questions, clinical flags, and contextual symptom trends. The freemium model offers the AI-powered organization layer for free, with professional-reviewed guidance (by trained healthcare professionals, not just algorithms) available for $19 per month. The focus on a human-in-the-loop model distinguishes myStoria from pure AI diagnostic tools and is likely to ease regulatory friction as the FDA continues to scrutinize AI-in-medical-device classifications.

The problem myStoria addresses is well-documented in reproductive health specifically: the average diagnostic delay for endometriosis is 7 to 10 years, driven partly by how fragmented and dismissal-prone the care pathway is. Patients frequently see 3 to 7 clinicians before receiving a diagnosis, and each new clinician typically starts from scratch because medical records don't travel cleanly across systems. myStoria's platform is designed to give patients a persistent, portable, AI-organized record that walks into every appointment with them. The company plans to expand across the full reproductive health lifecycle — from menstrual tracking and fertility management through perimenopause — making it a longitudinal health partner rather than a point-in-time tool.

Sources

Update — 2026-04-11

Initial entry — story first created.